YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Codexis, Inc. REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pione…
Codexis, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance and Operational Context Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick.…
Earnings Call Insights: Codexis (CDXS) Q2 2026 MANAGEMENT VIEW * CEO Alison Moore said Codexis delivered “solid financial results for the second quarter of 2026 with revenue of $14.9 million” and highlighted that a financing “resulted in a…
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $1.8 per share a year ago. These figures are adjusted for non-recurring i…
[Wall Street-Street Sign] P_Wei/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell Friday. Stock index futures were higher on Friday as the stock market hoped to recover from Thursday's sel…
(RTTNews) - Codexis, Inc. (CDXS), a provider of enzymatic solutions, announced the pricing of its public offering of 16.67 million shares at a price of $1.50 per share. The company expects net proceeds of approximately $23.1 million, which…
* Codexis (CDXS [https://seekingalpha.com/symbol/CDXS]) priced [https://seekingalpha.com/pr/20594336-codexis-announces-pricing-of-public-offering-of-common-stock] a public offering of 16.67M common shares at $1.50/share, at the bottom of i…
REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced the pricing o…
Codexis, Inc. REDWOOD CITY, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Codexis, a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, shared new advances in RNA therapeuti…
Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. In light of these conditions, investors may find value in smaller or newer…
Image source: The Motley Fool. Date Thursday, May 7, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Alison Moore Chief Financial Officer — Georgia Erbez Chief Commercial Officer — Britton Jimenez Need a quote from a Motle…
Codexis logo Key Points Interested in Codexis, Inc.? Here are five stocks we like better. Codexis reported Q1 2026 revenue of $15.2 million (up from $7.5M a year earlier), improved product gross margin to 71%, narrowed its net loss to $8.7…
Codexis (CDXS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings pictu…
The U.S. market has experienced a notable climb, rising 1.2% in the last week and 33% over the past year, with earnings projected to grow significantly in the coming years. In such a robust market climate, identifying stocks with strong fi…
Codexis, Inc. (NASDAQ:CDXS) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. On March 12, Matt Hewitt of Craig-Hallum reiterated his Buy rating on Codexis, Inc. (NASDAQ:CDXS). Just a day prior to this, TD Cowen analyst Brenda…
In March 2026, Codexis reported that Q4 2025 revenue rose to US$38.92 million with net income of US$9.6 million, while full-year revenue reached US$70.39 million alongside a reduced net loss and new 2026 revenue guidance of US$72–76 millio…
Codexis, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Platform Validation Shifted the ECOsynthesis platform from technical feasibility to supporting preclinical development, targeting a $2 billion addressable market fo…
Earnings Call Insights: Codexis (CDXS) Q4 2025 MANAGEMENT VIEW * CEO Alison Moore stated that Codexis is now focused on RNA medicine and has developed the ECO Synthesis manufacturing platform to address challenges in current siRNA producti…
Codexis logo Key Points Codexis is focused on scaling its ECO Synthesis enzymatic siRNA platform, hitting a 2025 milestone by synthesizing 10 grams of a commercially relevant siRNA, operating at 100‑gram scale in its lab with a target of 0…
Codexis, Inc. REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will re…
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.09 per share a year ago. These figures are adjusted for non-recurring item…
Incyte (INCY) came out with quarterly earnings of $1.8 per share, missing the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of $1.43 per share a year ago. These figures are adjusted for non-recurring items. This qu…
REDWOOD CITY, Calif., Jan. 7, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of LGC Group, an oligonucleotide Contract Re…
Dr. Bluestone to serve as Advisor to the Company and remain on Board of Directors Dr. Dilly to bring track record in biopharmaceutical leadership, business development and drug development to new leadership role CEO transition to drive nex…
A downtrend has been apparent in Codexis (CDXS) lately with too much selling pressure. The stock has declined 30% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly i…
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a leas…
Codexis, Inc. REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has…
This article first appeared on GuruFocus. Release Date: November 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Codexis Inc (NASDAQ:CDXS) signed a supply assura…
Codexis (CDXS) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items. This quarte…
REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Codexis Inc. (CDXS) on Thursday reported a loss of $19.6 million in its third quarter. The Redwood City, California-based company said it had a loss of 22 cents per share. The produce…
Codexis, Inc. Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE…
Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis,…
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.54 per share a year ago. These figures are adjusted for non-recurring i…
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.61 per share a year ago. These figures are adjusted for non-recurrin…
REDWOOD CITY, Calif., Oct. 29, 2025 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avecia, Inc. a leading contract development…
Codexis, Inc. REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it wil…